* Sutro Biopharma Inc is expected to show a fall in quarterly revenue when it reports results on May 13 (estimated) for the period ending January 1 0001
* The South San Francisco California-based company is expected to report a 4.8% decrease in revenue to $12.071 million from $12.67 million a year ago, according to the mean estimate from 10 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Sutro Biopharma Inc is for a loss of 92 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Sutro Biopharma Inc is $12.00, above its last closing price of $4.35.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.82 0.52 Beat 163.2
Sep. 30 2023 -0.74 -0.74 -0.81 Missed -10.1
Jun. 30 2023 -0.75 -0.73 -0.64 Beat 12.6
Jan. 1 0001 -0.80 -0.81 -0.85 Missed -4.8
Dec. -0.61 -0.62 -0.68 Missed -9.5
31 2022
Sep. 30 2022 -0.75 -0.74 -0.37 Beat 49.9
Jun. 30 2022 -0.43 -0.46 -0.55 Missed -19.2
Jan. 1 0001 -0.77 -0.76 -0.84 Missed -10.9
This summary was machine generated May 10 at 16:06 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments